MBX Capital is a venture capital firm dedicated to investing in early-stage healthcare and biotechnology companies that address significant public health challenges. Founded in 2015 by Zeshan Muhammedi and Gurdane Bhutani, the firm is headquartered in Claymont, Delaware. ( MBX Capital focuses on startups that tackle the root causes of health issues, aiming to improve human health through innovative solutions.

The firm's investment strategy is agnostic to sector, provided the company addresses a clear root cause , with a typical first check between $1 to $2.5 million, seeking at least 5% ownership. ( As of June 4, 2024, MBX Capital's assets under management exceeded $100 million. ( The firm has a portfolio of over 30 biotech and healthcare companies, including Tidal Vision, Arine, and Vivodyne.

MBX Capital's Atom Network comprises hundreds of scientific, industry, and clinical experts who collaborate to identify and vet prospective partner companies and refine investment themes.